The Epithelial Sodium Channel-An Underestimated Drug Target.

Abstract

Epithelial sodium channels (ENaC) are part of a complex network of interacting biochemical pathways and as such are involved in several disease states. Dependent on site and type of mutation, gain- or loss-of-function generated symptoms occur which span from asymptomatic to life-threatening disorders such as Liddle syndrome, cystic fibrosis or generalized pseudohypoaldosteronism type 1. Variants of ENaC which are implicated in disease assist further understanding of their molecular mechanisms in order to create models for specific pharmacological targeting. Identification and characterization of ENaC modifiers not only furthers our basic understanding of how these regulatory processes interact, but also enables discovery of new therapeutic targets for the disease conditions caused by ENaC dysfunction. Numerous test compounds have revealed encouraging results in vitro and in animal models but less in clinical settings. The EMA- and FDA-designated orphan drug solnatide is currently being tested in phase 2 clinical trials in the setting of acute respiratory distress syndrome, and the NOX1/ NOX4 inhibitor setanaxib is undergoing clinical phase 2 and 3 trials for therapy of primary biliary cholangitis, liver stiffness, and carcinoma. The established ENaC blocker amiloride is mainly used as an add-on drug in the therapy of resistant hypertension and is being studied in ongoing clinical phase 3 and 4 trials for special applications. This review focuses on discussing some recent developments in the search for novel therapeutic agents.

• Authors: Rosa Lemmens-Gruber, Susan Tzotzos
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 24 Issue 9 (Apr 24 2023) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 37175488 (Publication Type: Journal Article, Review)

Chemical References

• Epithelial Sodium Channels
• Amiloride

Topics

• Animals
• Epithelial Sodium Channels (genetics, metabolism)
• Hypertension (metabolism)
• Liddle Syndrome
• Pseudohypoaldosteronism (metabolism)
• Amiloride (pharmacology)